BR9709661A - Processos para inibir a formação de trombos em um paciente, para manter ou melhorar a patência vascular em um paciente, para evitar ou minimizar o dano miocardìaco associado com reperfusão pós-isquêmica em um indivìduo, e, para melhorar o fluxo sanguìneo no miocárdio regional durante a reperfusão pós-isquêmica em um indivìduo, e, uso do fator vii - Google Patents

Processos para inibir a formação de trombos em um paciente, para manter ou melhorar a patência vascular em um paciente, para evitar ou minimizar o dano miocardìaco associado com reperfusão pós-isquêmica em um indivìduo, e, para melhorar o fluxo sanguìneo no miocárdio regional durante a reperfusão pós-isquêmica em um indivìduo, e, uso do fator vii

Info

Publication number
BR9709661A
BR9709661A BR9709661-0A BR9709661A BR9709661A BR 9709661 A BR9709661 A BR 9709661A BR 9709661 A BR9709661 A BR 9709661A BR 9709661 A BR9709661 A BR 9709661A
Authority
BR
Brazil
Prior art keywords
patient
individual
factor vii
ischemic reperfusion
post
Prior art date
Application number
BR9709661-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Lars Christian Petersen
Charles E Hart
Ulla Hedner
Mirella Ezban Rasmussen
Original Assignee
Novo Nordisk As
Zymogenetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As, Zymogenetics Inc filed Critical Novo Nordisk As
Publication of BR9709661A publication Critical patent/BR9709661A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A61K38/166—Streptokinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Materials For Medical Uses (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR9709661-0A 1996-06-07 1997-06-06 Processos para inibir a formação de trombos em um paciente, para manter ou melhorar a patência vascular em um paciente, para evitar ou minimizar o dano miocardìaco associado com reperfusão pós-isquêmica em um indivìduo, e, para melhorar o fluxo sanguìneo no miocárdio regional durante a reperfusão pós-isquêmica em um indivìduo, e, uso do fator vii BR9709661A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/660,289 US5833982A (en) 1991-02-28 1996-06-07 Modified factor VII
PCT/DK1997/000251 WO1997047651A1 (en) 1996-06-07 1997-06-06 Modified factor vii

Publications (1)

Publication Number Publication Date
BR9709661A true BR9709661A (pt) 2000-04-25

Family

ID=24648892

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9709661-0A BR9709661A (pt) 1996-06-07 1997-06-06 Processos para inibir a formação de trombos em um paciente, para manter ou melhorar a patência vascular em um paciente, para evitar ou minimizar o dano miocardìaco associado com reperfusão pós-isquêmica em um indivìduo, e, para melhorar o fluxo sanguìneo no miocárdio regional durante a reperfusão pós-isquêmica em um indivìduo, e, uso do fator vii

Country Status (17)

Country Link
US (2) US5833982A (OSRAM)
EP (1) EP0910580A1 (OSRAM)
JP (1) JP2000513720A (OSRAM)
KR (1) KR20000016415A (OSRAM)
CN (2) CN1515318A (OSRAM)
AU (1) AU735012B2 (OSRAM)
BR (1) BR9709661A (OSRAM)
CA (1) CA2256761A1 (OSRAM)
CZ (1) CZ394698A3 (OSRAM)
HU (1) HUP0003077A3 (OSRAM)
IL (1) IL127099A0 (OSRAM)
NO (1) NO985668L (OSRAM)
PL (1) PL330365A1 (OSRAM)
RU (1) RU2211704C2 (OSRAM)
UA (1) UA68333C2 (OSRAM)
WO (1) WO1997047651A1 (OSRAM)
ZA (1) ZA975013B (OSRAM)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5997864A (en) 1995-06-07 1999-12-07 Novo Nordisk A/S Modified factor VII
US20040087498A1 (en) * 1991-02-28 2004-05-06 Novo Nordisk Health Care Ag Modified factor VII
ATE454161T1 (de) * 1997-07-18 2010-01-15 Novo Nordisk Healthcare Ag Verwendung von fviia oder fviiai zur behandlung von endothelialer fehlfunktion bzw zur inhibierung der angiogenese
US7247708B2 (en) * 1997-10-23 2007-07-24 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6693075B1 (en) 1997-10-23 2004-02-17 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6747003B1 (en) 1997-10-23 2004-06-08 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6406488B1 (en) * 1998-08-27 2002-06-18 Heartstent Corporation Healing transmyocardial implant
EP0987274A1 (en) 1998-09-15 2000-03-22 Hoechst Marion Roussel Deutschland GmbH Factor VIIa Inhibitors
EP1059302A1 (en) 1999-06-08 2000-12-13 Aventis Pharma Deutschland GmbH Factor VIIa inhibitors
US6924359B1 (en) 1999-07-01 2005-08-02 Yale University Neovascular-targeted immunoconjugates
EP1095933A1 (en) 1999-10-30 2001-05-02 Aventis Pharma Deutschland GmbH Novel N-guanidinoalkylamides, their preparation, their use, and pharmaceutical preparations comprising them
ATE428445T1 (de) * 2000-02-11 2009-05-15 Bayer Healthcare Llc Gerinnungsfaktor vii oder viia konjugate
JP2003530847A (ja) 2000-04-12 2003-10-21 ヒューマン ゲノム サイエンシズ インコーポレイテッド アルブミン融合タンパク質
US7812132B2 (en) * 2000-04-28 2010-10-12 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US7220837B1 (en) 2000-04-28 2007-05-22 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
EP1162194A1 (en) 2000-06-06 2001-12-12 Aventis Pharma Deutschland GmbH Factor VIIa inhibitory (thio)urea derivatives, their preparation and their use
US6833357B2 (en) * 2000-06-20 2004-12-21 The Trustees Of The University Of Pennsylvania Compositions and methods for modulating muscle cell and tissue contractility
US20030211094A1 (en) * 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
US6423826B1 (en) 2000-06-30 2002-07-23 Regents Of The University Of Minnesota High molecular weight derivatives of vitamin K-dependent polypeptides
US7160540B2 (en) * 2000-06-30 2007-01-09 Regents Of The University Of Minnesota Methods for detecting activity of clottings factors
WO2002046159A1 (en) 2000-12-06 2002-06-13 Aventis Pharma Deutschland Gmbh Guanidine and amidine derivatives as factor xa inhibitors
US6825323B2 (en) * 2001-01-10 2004-11-30 The United States Of America As Represented By The Secretary Of The Army Compositions for treatment of hemorrhaging with activated factor VIIa in combination with fibrinogen and methods of using same
ES2432967T3 (es) * 2001-03-22 2013-12-05 Novo Nordisk Health Care Ag Derivados del Factor VII de coagulación
US7235638B2 (en) 2001-03-22 2007-06-26 Novo Nordisk Healthcare A/G Coagulation factor VII derivatives
CN1522151A (zh) * 2001-05-02 2004-08-18 ŵ��Ų�ڿ˹�˾ 经修饰的fvii用于治疗ards
EP1270551A1 (en) 2001-06-26 2003-01-02 Aventis Pharma Deutschland GmbH Urea derivatives with antiproteolytic activity
WO2003022122A2 (en) * 2001-09-10 2003-03-20 Florence Medical Ltd. Individual ffr determination for lesions of a multi-lesioned blood vessel
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
EP2305313B1 (en) 2001-10-10 2014-03-26 ratiopharm GmbH Remodelling and glycoconjugation of interferon-alpha (IFNa)
AU2002336920A1 (en) * 2001-11-02 2003-05-12 Novo Nordisk Health Care Ag Use of tissue factor agonist or tissue factor antagonist for treatment of conditions related to apoptosis
EP1314733A1 (en) 2001-11-22 2003-05-28 Aventis Pharma Deutschland GmbH Indole-2-carboxamides as factor Xa inhibitors
PL370652A1 (en) 2001-12-21 2005-05-30 Novo Nordisk Health Care Ag Liquid composition of factor vii polypeptides
KR20040065278A (ko) * 2001-12-21 2004-07-21 노보 노르디스크 에이/에스 변경된 인자 ⅶ 폴리펩티드의 액체 조성물
BR0215218A (pt) * 2001-12-21 2004-11-16 Novo Nordisk As Composição aquosa lìquida, método para a preparação da mesma, uso de uma composição, e, métodos para a inibição da coagulação do sangue em um indivìduo, e inibição de reações mediadas pelo fator de tecido em um indivìduo
SI1499719T1 (sl) * 2002-04-30 2011-03-31 Bayer Healthcare Llc Polipeptidne variante faktorja VII ali VIIa
US20040009918A1 (en) * 2002-05-03 2004-01-15 Hanne Nedergaard Stabilised solid compositions of modified factor VII
ATE536886T1 (de) * 2002-05-03 2011-12-15 Novo Nordisk As Stabilisierte feste zusammensetzungen von modifizierter faktor vii
CN1671410B (zh) * 2002-06-21 2010-05-12 诺和诺德医疗保健公司 因子ⅶ多肽的稳定化固体组合物
DK1549677T3 (da) * 2002-09-30 2011-07-18 Bayer Healthcare Llc FVII- eller FVIIa-varianter med forøget koagulationsaktivitet
US7358268B2 (en) 2002-12-04 2008-04-15 Sanofi-Aventis Deutschland Gmbh Imidazole derivatives as factor Xa inhibitors
US7429581B2 (en) 2002-12-23 2008-09-30 Sanofi-Aventis Deutschland Gmbh Pyrazole-derivatives as factor Xa inhibitors
US20040176704A1 (en) * 2003-03-04 2004-09-09 Stevens Timothy A Collection device adapted to accept cartridge for point of care system
JP2006524195A (ja) * 2003-03-18 2006-10-26 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト Ｖｉｉ因子ポリペプチドの液状水性医薬組成物
WO2004083361A2 (en) * 2003-03-20 2004-09-30 Maxygen Holdings Ltd. FVII OR FVIIa VARIANTS
US7897734B2 (en) * 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
EP2055189A1 (en) 2003-04-09 2009-05-06 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
US20040202726A1 (en) * 2003-04-10 2004-10-14 Deshay Samuel L. Topical blood pressure composition
EP1479677A1 (en) 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH New indole derivatives as factor xa inhibitors
EP1479675A1 (en) 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH Indazole-derivatives as factor Xa inhibitors
EP1479680A1 (en) 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH Azaindole derivatives as Factor Xa inhibitors
US7741341B2 (en) 2003-05-19 2010-06-22 Sanofi-Aventis Deutschland Gmbh Benzimidazole-derivatives as factor Xa inhibitors
US7317027B2 (en) 2003-05-19 2008-01-08 Sanofi-Aventis Deutschland Gmbh Azaindole-derivatives as factor Xa inhibitors
US7223780B2 (en) 2003-05-19 2007-05-29 Sanofi-Aventis Deutschland Gmbh Triazole-derivatives as blood clotting enzyme factor Xa inhibitors
BRPI0409936A (pt) * 2003-05-23 2006-04-25 Novo Nordisk Healthcare Ag uso de um material, recipiente pelo menos parcialmente cheio, e, kit médico
US7029675B1 (en) * 2003-06-04 2006-04-18 Shu-Wha Lin Hepsin antagonist and methods of use
MXPA05013769A (es) * 2003-06-19 2006-03-08 Maxygen Holdings Ltd Variantes del dominio gla del factor vii o viia.
WO2004112828A1 (en) 2003-06-25 2004-12-29 Novo Nordisk Health Care Ag Liquid composition of factor vii polypeptides
JP5306597B2 (ja) * 2003-07-01 2013-10-02 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 第ｖｉｉ因子ポリペプチドの液体水性薬学的組成物
US9005625B2 (en) 2003-07-25 2015-04-14 Novo Nordisk A/S Antibody toxin conjugates
MXPA06001698A (es) 2003-08-14 2006-05-19 Novo Nordisk Healthcare Ag Composicion farmaceutica liquida y acuosa de polipetidos de factor vii.
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
DK2298287T3 (en) * 2003-12-19 2018-07-23 Novo Nordisk Healthcare Ag Stabilized compositions of factor VII polypeptides
EP1568698A1 (en) 2004-02-27 2005-08-31 Aventis Pharma Deutschland GmbH Pyrrole-derivatives as factor Xa inhibitors
JP2008514216A (ja) * 2004-09-29 2008-05-08 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト Ｄｅｓｇｌａ−ｖｉｉ因子ポリペプチド構造の除去による、ｖｉｉ因子ポリペプチドの原体の精製
JP5948627B2 (ja) 2004-10-29 2016-07-20 レイショファーム ゲーエムベーハー 線維芽細胞成長因子（ｆｇｆ）のリモデリングと糖質ペグ化
WO2006074467A2 (en) 2005-01-10 2006-07-13 Neose Technologies, Inc. Glycopegylated granulocyte colony stimulating factor
WO2006121569A2 (en) 2005-04-08 2006-11-16 Neose Technologies, Inc. Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
US20090048440A1 (en) 2005-11-03 2009-02-19 Neose Technologies, Inc. Nucleotide Sugar Purification Using Membranes
US20080242607A1 (en) 2006-07-21 2008-10-02 Neose Technologies, Inc. Glycosylation of peptides via o-linked glycosylation sequences
US8969532B2 (en) 2006-10-03 2015-03-03 Novo Nordisk A/S Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography
CA2682897C (en) 2007-04-03 2016-11-22 Biogenerix Ag Methods of treatment using glycopegylated g-csf
WO2008154639A2 (en) 2007-06-12 2008-12-18 Neose Technologies, Inc. Improved process for the production of nucleotide sugars
KR101582841B1 (ko) 2008-02-27 2016-01-11 노보 노르디스크 에이/에스 콘쥬게이트된 인자 ｖｉｉｉ 분자
US8466108B2 (en) 2008-12-19 2013-06-18 Baxter International Inc. TFPI inhibitors and methods of use
AU2010290131C1 (en) 2009-08-24 2015-12-03 Amunix Operating Inc. Coagulation factor VII compositions and methods of making and using same
AU2011227714B2 (en) 2010-03-19 2014-09-04 Takeda Pharmaceutical Company Limited TFPI inhibitors and methods of use
KR101294351B1 (ko) * 2010-05-27 2013-08-07 동국대학교 산학협력단 뇌혈전 형광영상기술을 이용한 뇌졸중 동물모델의 뇌경색 영역의 크기 예측 방법
EA201491470A1 (ru) 2012-02-15 2015-01-30 Амуникс Оперэйтинг Инк. Композиции фактора viii и способы получения и использования подобных
HRP20190454T1 (hr) 2012-02-15 2019-05-03 Bioverativ Therapeutics Inc. Rekombinantni faktor viii proteini
CN104302306B (zh) 2012-03-21 2019-03-22 百深有限责任公司 Tfpi抑制剂及其使用方法
WO2015023891A2 (en) 2013-08-14 2015-02-19 Biogen Idec Ma Inc. Factor viii-xten fusions and uses thereof
RU2018106348A (ru) * 2015-07-22 2019-08-22 Айконик Терапьютикс, Инк. Способы лечения расстройств, связанных с ангиогенезом и неоваскуляризацией
WO2017024060A1 (en) 2015-08-03 2017-02-09 Biogen Ma Inc. Factor ix fusion proteins and methods of making and using same
CA3010310C (en) 2016-01-15 2022-11-22 Rigshospitalet A positron-emitting 18-f labelled factor viia (fviia) imaging agent and method of use thereof
WO2018091058A1 (en) 2016-11-17 2018-05-24 Rigshospitalet 177-lu labeled active site inhibited factor vii
CA3045660A1 (en) 2016-12-02 2018-06-07 Bioverativ Therapeutics Inc. Methods of treating hemophilic arthropathy using chimeric clotting factors
MX2020012397A (es) 2018-05-18 2021-04-12 Bioverativ Therapeutics Inc Metodos de tratamiento de la hemofilia a.

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775624A (en) * 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
GR860984B (en) * 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
WO1986006408A1 (en) * 1985-04-22 1986-11-06 Genetics Institute, Inc. HIGH YIElD PRODUCTION OF ACTIVE FACTOR IX
US4959318A (en) * 1985-06-27 1990-09-25 Zymogenetics, Inc. Expression of protein C
US4829052A (en) * 1986-06-11 1989-05-09 Monsanto Company Serine protease inhibitors
US5258288A (en) * 1986-07-25 1993-11-02 Genzyme Corporation Vector containing DNA encoding mature human protein S
JPS63290852A (ja) 1987-02-10 1988-11-28 グラクソ、グループ、リミテッド 化合物
FR2619314B1 (fr) * 1987-08-11 1990-06-15 Transgene Sa Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant
US4994371A (en) * 1987-08-28 1991-02-19 Davie Earl W DNA preparation of Christmas factor and use of DNA sequences
US5023236A (en) * 1988-04-07 1991-06-11 Corvas, Inc. Factor VII/VIIA active site inhibitors
US5258180A (en) * 1988-09-02 1993-11-02 Genetech, Inc. Tissue plasminogen activator having fibrin specific properties and deletion of amino acids 466-970, compositions and methods of treatment
WO1990003390A1 (en) * 1988-09-23 1990-04-05 Corvas, Inc. Peptidyl inhibitors of the initiation of coagulation
US5120537A (en) * 1989-06-14 1992-06-09 Oklahoma Medical Research Foundation Factor xa based anticoagulant compositions
US5190919A (en) * 1989-11-13 1993-03-02 Board Of Regents, The University Of Texas System Antihemostatic factor vii peptides
EP0521873B1 (en) * 1990-01-29 1999-06-02 Zymogenetics, Inc. Anticoagulant proteins
US5278144A (en) * 1990-09-04 1994-01-11 Cor Therapeutics, Inc. Antithrombosis agents
US5788965A (en) 1991-02-28 1998-08-04 Novo Nordisk A/S Modified factor VII
US5817788A (en) 1991-02-28 1998-10-06 Zymogenetics, Inc. Modified factor VII
EP0575464B1 (en) * 1991-02-28 2004-08-11 Zymogenetics, Inc. Modified factor vii
US5861374A (en) 1991-02-28 1999-01-19 Novo Nordisk A/S Modified Factor VII
RU2022561C1 (ru) * 1991-03-05 1994-11-15 Харьковский государственный университет им.А.М.Горького Противоишемическое средство
US5326559A (en) * 1991-05-16 1994-07-05 Miller D Douglas Treatment of accelerated atheosclerosis with interleukin-2 receptor targeted molecules
US5419760A (en) * 1993-01-08 1995-05-30 Pdt Systems, Inc. Medicament dispensing stent for prevention of restenosis of a blood vessel
GB9301093D0 (en) * 1993-01-20 1993-03-10 Rca Thomson Licensing Corp Digital video tape recorder for digital hdtv
CA2162726A1 (en) * 1993-05-21 1994-12-08 Kathleen L. Berkner Modified factor vii
US5648331A (en) * 1994-08-26 1997-07-15 G.D. Searle & Co. Method of inhibiting tissue ischemia and reperfusion injury

Also Published As

Publication number Publication date
CN1131872C (zh) 2003-12-24
AU3090697A (en) 1998-01-07
JP2000513720A (ja) 2000-10-17
NO985668L (no) 1999-02-04
IL127099A0 (en) 1999-09-22
CN1515318A (zh) 2004-07-28
CZ394698A3 (cs) 1999-04-14
NO985668D0 (no) 1998-12-04
AU735012B2 (en) 2001-06-28
WO1997047651A1 (en) 1997-12-18
RU2211704C2 (ru) 2003-09-10
KR20000016415A (ko) 2000-03-25
PL330365A1 (en) 1999-05-10
US5833982A (en) 1998-11-10
CN1221427A (zh) 1999-06-30
UA68333C2 (en) 2004-08-16
CA2256761A1 (en) 1997-12-18
HUP0003077A3 (en) 2003-01-28
HUP0003077A2 (hu) 2000-12-28
EP0910580A1 (en) 1999-04-28
ZA975013B (en) 1997-12-08
US6168789B1 (en) 2001-01-02

Similar Documents

Publication Publication Date Title
BR9709661A (pt) Processos para inibir a formação de trombos em um paciente, para manter ou melhorar a patência vascular em um paciente, para evitar ou minimizar o dano miocardìaco associado com reperfusão pós-isquêmica em um indivìduo, e, para melhorar o fluxo sanguìneo no miocárdio regional durante a reperfusão pós-isquêmica em um indivìduo, e, uso do fator vii
ES2169074T3 (es) Factor vii modificado para inhibir la reestenosis vascular o el deposito de plaquetas.
MX9702951A (es) Factor vii modificado.
ATE273393T1 (de) Modifizierter faktor-vii
Weksler et al. Human leukocyte cathepsin G and elastase specifically suppress thrombin-induced prostacyclin production in human endothelial cells
BR9915701A (pt) Composto, droga contendo um composto, e, uso de um composto
FI922325A0 (fi) Oral sammansaettning foer botning av inflammatoriska tarmkanalsjukdomar.
MX9504415A (es) Eteres antivirales de isoesteres de sustrato de proteasa de aspartato.
BR0012136A (pt) Inibidores de reabsorção de norepinefrina altamente seletivos e métodos de uso dos mesmos
ES2131973T3 (es) Empleo de 2-amino-4-(4-fluorobencilamino)-1-etoxicarbonilaminobencenos para la profilaxis y el tratamiento de las secuelas de la disminucion aguda y cronica del riego sanguineo cerebral, asi como de afecciones neurodegenerativas.
SE9701162D0 (sv) New use II
ATE188119T1 (de) Heilmittel für wunden und hämorrhoiden
DK261490D0 (da) New pharmaceutical compound
ATE332128T1 (de) Entzündungshemmende ascorbinsäurederivate
Passannante et al. Case report: the heparin flush syndrome: a cause of iatrogenic hemorrhage
BR9916318A (pt) Compostos bicìclicos
ATE200422T1 (de) Verwendung von boswelliasäure und ihren derivaten zur hemmung der normalen und gesteigerten leukozytenelastase- oder plasminaktivität
ATE187642T1 (de) Verwendund von norastemizol zur behandlung der allergischen rhinitis
KR930702019A (ko) 피부.각막 질환 치료제
FI952593A0 (fi) Hyytymistä estävä aine
ID26965A (id) Obat untuk mencegah dan/atau mengobati kanker payudara, yang mengandung inhibitor aromatase steroid
BR0113372A (pt) Composição farmacêutica com carreador modificado, método de fabricação da mesma e seus usos
BR9809478A (pt) Uso de um oligossacarìdeo sintético, processos para prevenção de coagulação sanguìnea em um mamìfero e para prevenção de coagulação sanguìnea e um circuito sanguìneo extracorpóreo, e, composição farmacêutica adaptada para prevenir coagulação sanguìnea em um circuito sanguìneo extracorpóreo
KR960701657A (ko) 피부 상처 치료용 인자 XIII (Factor XIII for treatment of skin wounds)
DE69943240D1 (de) Verwendung von HGF für die Behandlung von ischämischen Erkrankungen der Extremitäten

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1882 DE 30/01/2007.